Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024623 (
gastric cancer
)
36,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Gastric cancer
(GC) represents the third leading cause of cancer-related deaths worldwide. The levels of prostaglandin E
2
, a key player in the hallmarks of cancer, are mainly regulated by prostaglandin-endoperoxide synthase 2 (PTGS2) and ATP-binding cassette subfamily C member 4 (ABCC4), involved in its synthesis and exportation, respectively, and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and solute carrier organic anion transporter family member 2A1 (SLCO2A1), responsible for its inactivation. Even though there are distinct molecular signatures across ethnic populations, most published studies focus on Asian populations. Our main aim was to explore the genetic expression of the aforementioned molecules in a Caucasian population. 94 "Normal" and 89 tumoral formalin-fixed paraffin-embedded (FFPE) samples from GC patients were used to assess the mRNA expression of
PTGS2
,
ABCC4
, hydroxyprostaglandin dehydrogenase 15-(NAD) (
HPGD)
,
SLCO2A1
by Real-Time PCR. We found an upregulation for the
PTGS2
gene mean factor of 2.51 and a downregulation for the
HPGD
and
SLCO2A1
genes (mean factor of 0.10 and 0.37, respectively) in tumorous mucosa in a gender-independent manner. In females, we observed an
ABCC4
downregulation and a
PTGS2
mRNA upregulation compared to males in tumoral mucosa (mean factor of 0.61 and 1.64, respectively). We reported dysregulation of the inflammation triggered
PGE
2
pathway in a Caucasian population with an intermediate risk for GC, which might highlight the applicability of aspirin in the treatment of GC patients.
...
PMID:Prostaglandin E
2
Pathway Is Dysregulated in Gastric Adenocarcinoma in a Caucasian Population. 3308 78
<< Previous
1
2
3
4
5